Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | USP7 | Q93009 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13393866 | 0.91 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12136833 | 0.91 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12447479 | 0.91 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL82945 | 0.91 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL82937 | 0.91 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL82953 | 0.90 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10175977 | 0.90 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL84160 | 0.89 | NOS2 (0.63) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12447445 | 0.88 | MBOAT4 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL83431 | 0.88 | MBOAT4 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090574-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-RE45325-E1 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-RE45288-E1 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140179928-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8440820-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120245374-A1 | Antioxidant Inflammation Modulators: Oleanolic Acid Derivatives with Saturation in the C-Ring | REATA PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8124656-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7915402-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245374-A1 | Antioxidant Inflammation Modulators: Oleanolic Acid Derivatives with Saturation in the C-Ring | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
| US-20140179928-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.